tiprankstipranks
Blurbs

EyePoint Pharmaceuticals (EYPT) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on EyePoint Pharmaceuticals (EYPTResearch Report) today and set a price target of $24.00. The company’s shares closed last Friday at $10.00.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 18.6% and a 37.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

EyePoint Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $29.50.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $21.50 and a one-year low of $7.30. Currently, EyePoint Pharmaceuticals has an average volume of 796.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Read More on EYPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed